Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RK018
- Development stage
- Preclinical
- Lead developer
- RevolKa
- Modality
- Recombinant Proteins and Enzymes
01
Overview
RK018 is a protein-based therapeutic candidate currently in the early development stage at RevolKa. The drug was developed using RevolKa's proprietary protein engineering platform, which utilizes artificial intelligence and directed evolution to optimize protein functions and properties. As of the current pipeline disclosures, RevolKa has not released specific information regarding the molecular target, mechanism of action, or the primary therapeutic indication for RK018, though it is categorized within their protein modality portfolio.
- Other names
- RK018-RevolKa-proteinRK-018-RevolKa-proteinRK 018-RevolKa-protein
Beyond the preview
Go deeper on RK018.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RK018.